Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is moving its lead drug candidate, Lucid-MS, into a Phase 2 clinical trial for multiple sclerosis, according to comments made by co-founder and Executive Co-Chair Anthony Durkacz on The BioMedWire Podcast. The trial will be the first time the drug is tested in patients with multiple sclerosis, marking a significant step for the company and potentially for the treatment landscape of the disease.
Lucid-MS is a patented new chemical entity that targets myelin, the protective sheath around nerve fibers that is damaged in multiple sclerosis. In preclinical models, the drug has been shown to prevent and reverse myelin degradation, the underlying mechanism of the disease. If the Phase 2 trial confirms these effects in humans, Lucid-MS could offer a novel approach to treating MS, a condition that affects millions worldwide and currently has no cure. The news is particularly relevant for investors and patients awaiting new therapeutic options.
Durkacz also discussed unbuzzd™, a product designed to accelerate alcohol metabolism. Quantum BioPharma invented unbuzzd™ and spun out its over-the-counter version to Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), a company led by industry veterans. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and is entitled to royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. This arrangement provides Quantum with a potential long-term revenue stream while allowing it to focus on its pharmaceutical development.
The commercial opportunity for unbuzzd™ lies in the growing consumer interest in products that mitigate the effects of alcohol consumption. With a royalty stream that could reach $250 million, Quantum has positioned itself to benefit from the product's success without bearing the full costs of marketing and distribution. The company also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses, preserving future upside in the medical market.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. The progress of this drug candidate and the royalty agreement for unbuzzd™ are central to Quantum's strategy and could significantly impact its valuation.
For those following the company, the latest updates are available in its newsroom at Quantum BioPharma Ltd. and via Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM). The full press release can be viewed at https://ibn.fm/ovRTM.
BioMedWire, the platform that hosted the podcast, is a specialized communications outlet focused on biotechnology, biomedical sciences, and life sciences. It is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution. These services help companies like Quantum BioPharma reach a broad audience of investors and industry stakeholders.
